AACR 2025 Poster 5195

Development of Paired PDX-PDXO Preclinical Models for HER2-Targeting ADC Efficacy Evaluation

Jinxi Wang, Jun Zhou, Limei Shang, Qingzhi Liu, Binchen Mao, Rongfei Lu, Yi Sun, Peng Han, Lin Zhang, Likun Zhang, Xiaolong Tu, Wubin Qian, Peng Wang, Leilei Chen, Marten Hornsveld, Marrit Putker, Ludovic Bourre, Jessie J.J. Wang

HER2 amplification is a key factor in breast and gastric cancers. Our paired Patient-Derived Xenograft (PDX) and PDX-Derived Organoid (PDXO) models offer a powerful preclinical platform to study HER2-targeted therapies. These models closely correlate in response to DS8201 (Enhertu), enabling deeper insights into drug efficacy, resistance mechanisms, and next-generation treatment strategies. Download our poster to explore the data and translational potential of these innovative models.

Download this Poster to Discover:

• Comprehensive Model Development: Paired PDX and PDXO models from breast and gastric cancers enable robust in vitro and in vivo studies for HER2-targeted therapy development.
  
  
• DS8201 Sensitivity in HER2 Models: High HER2 expression correlated with DS8201 sensitivity, while some HER2-negative breast cancer models responded, suggesting a bystander effect.
  
  
• PDX-PDXO Correlation Strong DS8201 sensitivity correlation between PDX and PDXO models supports PDXOs as reliable translational models for preclinical drug evaluation.

Download the Poster Now!